A stabilised form of methylene blue which is a first-in-class tau aggregation inhibitor being developed for the treatment of mild to moderate Alzheimer's disease and behavioural variant frontotemporal dementia. Postulated to act by preventing the formation and spread of neurofibrillary tangles. Phase III trials should report in 2015.
Oral 150mg or 250mg twice daily
Cautions and Interactions
- Blue dye
Enzyme converted in the stomach from the stabilised, reduced form of charged leuco-methylthioninium chloride to uncharged leuco-methylthioninium prior to absorption.